Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2012. The report details specific corporate actions regarding share repurchases and cancellations executed on September 20, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes:
- Shares Purchased: 1,600,000 Ordinary Shares of 25 pence each.
- Purchase Price Range: Highest price paid was 1,439.5 pence per share; lowest price paid was 1,427.5 pence per share.
- Shares Cancelled: 30,000,000 Treasury shares.
- Treasury Holdings: 491,265,427 shares held in Treasury (9.02% of total issued share capital).
- Total Voting Rights: 4,952,195,216 shares in issue (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share count through the cancellation of 30 million Treasury shares and the acquisition of an additional 1.6 million shares for Treasury. Consequently, the total number of shares held in Treasury now represents 10.01% of the current total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the impact of the 30 million share cancellation on the total issued share capital.
- Confirm the current percentage of Treasury shares relative to total voting rights (reported as 10.01% including unsettled shares).
- Check the average price paid for the 1.6 million repurchased shares against the reported range of 1,427.5 to 1,439.5 pence.
- Ensure the denominator for shareholder notification thresholds is updated to 4,952,195,216 shares.